In the Brazilian pharmaceutical industry, there were 5 M&A deals announced in Q2 2023, worth a total value of $349.7m, according to GlobalData’s Deals Database. The $242.3m minority acquisition of hypera by votorantim was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, M&A activity in Brazil increased by 751% in Q2 2023 compared with the previous quarter’s total of $41.1m and fell by 29% as compared to Q2 2022. Related deal volume decreased by 29% in Q2 2023 versus the previous quarter and was 29% lower than in Q2 2022.
The top-ranked legal advisorss supporting these M&A deals in Brazil Q2 2023 were Lefosse Advogados; Machado, Meyer, Sendacz e Opice Advogados; Madrona Fialho Advogados with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.